Tasca is a privately held biotechnology company focused on discovering and developing small molecule inhibitors of auto-palmitoylated target proteins important in cancer. The Company's lead program, CP-383, is a first-in-class drug candidate, with promising preclinical activity against multiple cancer types.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/11/24 | $52,000,000 | Series A |
Cure Ventures Invus Group Regeneron Ventures | undisclosed |
